What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Sanger Sequencing vs NGS: Mechanisms, Trade-offs, and Choosing the Right Method

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

DNA sequencing has undergone a dramatic evolution over the past four decades, yet the fundamental choice between Sanger sequencing and next-generation sequencing (NGS) remains a central decision in molecular biology laboratories. Sanger sequencing, developed by Frederick Sanger in 1977, was the workhorse of the Human Genome Project and remains the gold standard for accuracy in targeted applications. NGS technologies, which emerged commercially in the mid-2000s, transformed genomics by enabling massively parallel sequencing of millions of DNA fragments simultaneously. Understanding the mechanistic differences between these approaches—not just their throughput—is essential for selecting the appropriate method for a given biological question. This article provides a mechanistic comparison of Sanger sequencing and NGS, covering their core principles, workflow differences, error profiles, and practical decision-making frameworks.

Introduction to Sanger Sequencing and NGS

What is Sanger Sequencing?

Sanger sequencing, also known as the chain-termination method, is a capillary electrophoresis–based technique that determines the nucleotide sequence of a single, purified DNA template. The method relies on the incorporation of fluorescently labeled dideoxynucleotides (ddNTPs) that terminate DNA synthesis at specific positions. Each reaction produces a population of fragments of varying lengths, each ending at a particular nucleotide. These fragments are separated by size through capillary electrophoresis, and the fluorescence signal at each position reveals the identity of the terminal nucleotide.

Sanger sequencing produces high-quality reads of 600–1,000 base pairs (bp) per reaction, with per-base accuracy exceeding 99.9%. The method is inherently low-throughput: a single capillary instrument can process 96 or 384 samples per run, each yielding one sequence read. This makes Sanger sequencing ideal for applications requiring high accuracy on a limited number of targets, such as confirming variants identified by NGS, sequencing individual clones, or analyzing small numbers of PCR products.

What is Next-Generation Sequencing (NGS)?

Next-generation sequencing encompasses a family of technologies that perform massively parallel sequencing of millions to billions of DNA fragments in a single run. Unlike Sanger sequencing, which sequences one template at a time, NGS fragments the genome into small pieces, ligates universal adapters, and sequences all fragments simultaneously. The most widely adopted platforms—Illumina's sequencing-by-synthesis (SBS) and Thermo Fisher's Ion Torrent semiconductor sequencing—share this core architecture but differ in detection chemistry.

NGS generates read lengths ranging from 75 bp (short-read platforms) to 300 bp (paired-end reads on Illumina MiSeq), with some platforms such as Pacific Biosciences and Oxford Nanopore achieving much longer reads. The throughput ranges from approximately 1 million reads on benchtop instruments to over 20 billion reads on production-scale systems like the NovaSeq 6000. This scalability enables whole-genome, whole-exome, and transcriptome sequencing at costs that have fallen from $1,000 per megabase in 2004 to less than $0.01 per megabase today.

Core Principles of Sanger Sequencing

Chain Termination with ddNTPs

The Sanger method exploits the natural process of DNA polymerase–mediated synthesis, but with a critical modification: the inclusion of dideoxynucleotides that lack the 3′-hydroxyl group required for phosphodiester bond formation. When a ddNTP is incorporated into a growing DNA strand, chain elongation stops because no subsequent nucleotide can be attached.

The reaction mixture contains:

A single-stranded DNA template (typically 10–100 ng)
A specific primer (2–5 pmol) that anneals upstream of the region of interest
DNA polymerase I Klenow fragment or a thermostable polymerase such as Taq (1–2 units)
All four deoxynucleotide triphosphates (dNTPs) at concentrations of 100–200 μM
A small proportion (1–2%) of fluorescently labeled ddNTPs, each labeled with a distinct fluorophore (e.g., dideoxyadenosine with dichloroR110, dideoxycytosine with dichloroR6G, dideoxyguanosine with dichloroTAMRA, dideoxythymidine with dichloroROX)

The ratio of dNTPs to ddNTPs is critical. If the ddNTP concentration is too high, fragments terminate too early, producing short reads. If too low, fragments become excessively long and the signal degrades. Typical dNTP:ddNTP ratios range from 50:1 to 200:1, optimized for read lengths of 600–1,000 bp.

The reaction is performed in a thermal cycler using 25–35 cycles of:

Denaturation at 95°C for 30 seconds
Annealing at 50–60°C for 15 seconds (primer-specific)
Extension at 60°C for 4 minutes

Because each template molecule generates a population of fragments terminating at every possible position, the reaction produces a nested set of products differing in length by one nucleotide.

Capillary Electrophoresis and Detection

Following the termination reaction, the products are denatured and loaded onto a capillary array filled with a polymer matrix (typically polyacrylamide or a proprietary polymer such as POP-7). Capillary electrophoresis separates the fragments by size under an electric field of 300–400 V/cm. Smaller fragments migrate faster, so the fragments elute from the capillary in order of increasing length.

As each fragment passes through a laser detection window, the fluorophore is excited at its specific wavelength (e.g., 488 nm for argon-ion lasers), and the emitted fluorescence is recorded by a charge-coupled device (CCD) camera. The four ddNTPs are distinguished by their emission spectra, allowing the instrument to call the terminal nucleotide at each position.

The output is an electropherogram—a series of peaks where the x-axis represents fragment size (and thus position in the sequence) and the y-axis represents fluorescence intensity. Base calling software (e.g., Phred, which assigns quality scores) converts the electropherogram into a text sequence with associated quality values. The Phred quality score (Q) is defined as Q = −10 × log₁₀(P), where P is the probability of an incorrect base call. A Q20 score corresponds to 99% accuracy, Q30 to 99.9%, and Q40 to 99.99%.

For a detailed step-by-step protocol, see the Sanger Sequencing Protocol and the Sanger Sequencing Method.

Core Principles of Next-Generation Sequencing

Library Preparation and Adapter Ligation

NGS begins with the construction of a sequencing library—a collection of DNA fragments flanked by universal adapter sequences. The library preparation workflow varies by platform but generally follows these steps:

Fragmentation: Genomic DNA (100 ng–1 μg) is sheared by sonication (e.g., Covaris, which uses focused acoustics at 4–10°C), enzymatic digestion (e.g., NEBNext dsDNA Fragmentase), or tagmentation (e.g., Illumina Nextera, which uses a hyperactive Tn5 transposase that simultaneously fragments and ligates adapters).

End repair: Fragmented DNA ends are blunted using T4 DNA polymerase and T4 polynucleotide kinase, which removes 3′ overhangs and phosphorylates 5′ ends.

A-tailing: A single adenine is added to the 3′ ends using Klenow fragment (3′→5′ exo−) in the presence of dATP, creating a compatible overhang for adapter ligation.

Adapter ligation: Y-shaped adapters containing the sequencing primer binding sites, index sequences (6–10 bp), and flow cell binding sequences are ligated to the A-tailed fragments using T4 DNA ligase. The index sequences enable multiplexing—pooling multiple samples in a single run.

Size selection: Fragments of the desired length (typically 300–500 bp for short-read sequencing) are selected using AMPure XP beads (SPRI paramagnetic beads) or gel extraction. The bead-to-sample ratio determines the size cutoff; for example, a 0.6× bead ratio removes fragments >500 bp, while a 0.8× ratio removes >300 bp.

Amplification: The library is amplified by PCR (typically 8–12 cycles) to add sufficient material for cluster generation. Over-amplification introduces duplicate reads and biases, so cycle numbers are kept minimal.

For a comprehensive overview of this process, see Library Prep in Sequencing.

Clonal Amplification (Bridge PCR or Emulsion PCR)

Before sequencing, each individual library fragment must be amplified into a clonal cluster to generate a detectable signal. Two main approaches are used:

Bridge PCR (Illumina): The library is denatured to single strands and hybridized to a flow cell surface densely coated with two types of oligonucleotides (P5 and P7) complementary to the adapter sequences. Each bound fragment bends over and hybridizes to an adjacent complementary oligonucleotide, forming a bridge. DNA polymerase extends the bridge, creating a double-stranded molecule. Denaturation separates the strands, and each strand repeats the bridging process. After 30–35 cycles, each original fragment produces a cluster of approximately 1,000 identical copies within a ~1 μm diameter spot. The reverse strands are cleaved and washed away, leaving forward strands available for sequencing.

Emulsion PCR (Ion Torrent, 454): Library fragments are mixed with microbeads coated with complementary adapter sequences and compartmentalized into water-in-oil emulsion droplets. Each droplet contains one bead, one DNA fragment, and PCR reagents. Thermal cycling amplifies the fragment on the bead surface, producing ~10⁶ copies per bead. After breaking the emulsion, beads carrying clonally amplified templates are loaded into the wells of a semiconductor chip.

Sequencing-by-Synthesis and Base Calling

Illumina sequencing-by-synthesis: The flow cell is primed with a sequencing primer that anneals to the adapter sequence adjacent to the insert. The reaction incorporates fluorescently labeled, reversibly terminating nucleotides—each bearing a 3′-O-azidomethyl group that blocks further extension. In each cycle:

A mixture of all four labeled nucleotides (each with a distinct fluorophore) is introduced.
DNA polymerase incorporates one nucleotide complementary to the template.
Unincorporated nucleotides are washed away.
The flow cell is imaged with two lasers (e.g., 532 nm and 660 nm) to excite the fluorophores, and a CCD or CMOS camera captures images of the entire flow cell.
The fluorescent label and the 3′ block are cleaved chemically (using tris(2-carboxyethyl)phosphine, TCEP), regenerating the 3′-OH for the next cycle.

This cyclic process is repeated for the desired read length (75–300 cycles). Because all clusters are sequenced simultaneously, a single run generates millions to billions of reads. Base calling uses the fluorescence intensity at each cluster position, with software (e.g., Illumina's RTA, Real-Time Analysis) converting intensity signals to base calls with associated Phred-like quality scores.

Ion Torrent semiconductor sequencing: Instead of fluorescence, Ion Torrent detects hydrogen ions released during nucleotide incorporation. The chip contains millions of wells, each with a pH-sensitive ion-sensitive field-effect transistor (ISFET). Nucleotides are flowed sequentially (one at a time: A, C, G, T). When a nucleotide is incorporated, a hydrogen ion is released, causing a pH change proportional to the number of incorporated bases. Homopolymer regions (e.g., AAAA) produce a larger signal, but the signal is not linear beyond ~6–8 identical bases, leading to insertion/deletion (indel) errors in homopolymers.

Key Differences in Workflow and Throughput

Sample Preparation and Batching

Sanger sequencing requires a purified PCR product or plasmid as the template. The PCR product must be treated with exonuclease I and shrimp alkaline phosphatase (ExoSAP-IT) to remove primers and dNTPs, or purified by column or bead methods. Each sample is processed individually, and the sequencing reaction is set up in a single tube or well. This per-sample workflow is simple but limits scalability.

NGS library preparation is more complex and involves multiple enzymatic steps, as described above. However, the use of index adapters allows multiplexing—pooling up to 96 (or more) samples in a single run. This batching dramatically reduces the per-sample cost for large numbers of samples but introduces a minimum sample requirement to be cost-effective. For example, an Illumina MiSeq run costs approximately $1,000–$1,500 regardless of whether you sequence 1 sample or 96 samples; the per-sample cost drops from $1,000 to $15 as sample number increases.

Read Length and Number of Reads

Sanger sequencing produces a single read of 600–1,000 bp per reaction. The read length is limited by the resolution of capillary electrophoresis—beyond ~1,000 bp, the spacing between fragments becomes too small to resolve reliably.

NGS read lengths vary by platform:

Illumina: 75–300 bp (paired-end reads can be merged to span up to 600 bp)
Ion Torrent: 200–400 bp
Pacific Biosciences (SMRT): 10,000–25,000 bp (long-read)
Oxford Nanopore: 10,000–100,000+ bp (long-read)

The number of reads per run ranges from ~1 million (MiSeq) to ~20 billion (NovaSeq). This massive parallelism is the defining feature of NGS—it enables whole-genome sequencing at 30× coverage (i.e., each base is read an average of 30 times) in a single run.

Cost and Turnaround Time

The cost comparison between Sanger and NGS is nuanced. Sanger sequencing has a high per-base cost but a low upfront cost per sample. A single Sanger reaction costs approximately $3–$10 (excluding labor), producing ~700 bp of sequence. This translates to roughly $0.005–$0.015 per base.

NGS has a high upfront cost per run but a very low per-base cost. An Illumina MiSeq run (15 million reads, 300 bp paired-end) costs approximately $1,000–$1,500 and generates ~4.5 gigabases (Gb) of sequence. This translates to roughly $0.0000003 per base—four orders of magnitude cheaper than Sanger.

However, the total cost of NGS includes library preparation reagents ($30–$50 per sample), which can dominate for small sample numbers. For a single sample, Sanger sequencing is far cheaper. For 96 samples, NGS becomes competitive, and for whole-genome or transcriptome applications, NGS is the only practical option.

Turnaround time also differs. Sanger sequencing can be completed in 2–4 hours from purified template to sequence output. NGS requires 1–3 days for library preparation, 4–48 hours for sequencing (depending on platform and read length), and additional time for data analysis.

Accuracy, Error Profiles, and Data Quality

Sanger Accuracy and Limitations

Sanger sequencing is considered the gold standard for accuracy, with per-base accuracy exceeding 99.9% (Phred Q30 or higher) in the high-quality region (typically bases 20–700 of a 900 bp read). The error profile is characterized by:

Base-specific errors: Dye-labeled ddNTPs can cause mobility shifts, particularly for G and T, leading to peak spacing irregularities. Modern polymer formulations and base-calling algorithms largely correct for this.
Signal decay: The fluorescence signal decreases with fragment length due to incomplete extension and dye bleaching, reducing accuracy at the 3′ end of the read.
Homopolymer regions: Sanger sequencing handles homopolymers well because each base is incorporated in a separate termination event, producing discrete peaks.
Mixed templates: If the template contains a mixture of alleles (e.g., heterozygous variants), the electropherogram shows overlapping peaks. While this can be detected visually, accurate deconvolution of more than two alleles is difficult.

Sanger sequencing cannot detect variants present at low frequency (<10–20%) within a mixed population, limiting its utility for somatic mutation analysis or metagenomic applications.

NGS Error Sources and Phred Scores

NGS error profiles differ substantially from Sanger and vary by platform:

Illumina: The dominant error type is substitution, with error rates of 0.1–1% per base. Errors increase toward the 3′ end of reads due to:

Dephasing: Incomplete cleavage of the 3′ block or failure to incorporate a nucleotide in some clusters causes the signal to become asynchronous, degrading base-calling accuracy.
Fluorophore bleaching: Repeated laser excitation reduces signal intensity over cycles.
Sequence-specific errors: Certain motifs (e.g., GGC) cause polymerase stalling or misincorporation.

Ion Torrent: The dominant error type is insertion/deletion (indel), particularly in homopolymer regions. The pH-based detection cannot accurately quantify more than ~6–8 identical bases, leading to under- or over-calling of homopolymer length.

Quality scores: NGS platforms assign Phred-like quality scores to each base. For Illumina, these are calculated by RTA based on signal intensity, signal-to-noise ratio, and cluster quality. A Q30 score (99.9% accuracy) is the standard threshold for high-confidence variant calling, but the actual error rate varies by position, sequence context, and platform.

Coverage and consensus: The key to NGS accuracy is redundancy. By sequencing each base multiple times (coverage depth), errors can be distinguished from true variants. For example, a heterozygous variant should be present in ~50% of reads at a given position, while a sequencing error is typically present in <1% of reads. The __MASK_4__ resource provides a detailed explanation of how depth affects variant calling confidence.

Choosing Between Sanger and NGS: Applications and Suitability

When Sanger is Preferred

Sanger sequencing remains the method of choice for applications requiring high accuracy on a small number of targets:

Variant confirmation: Sanger sequencing is routinely used to validate variants identified by NGS, particularly clinically actionable variants. The high accuracy and low cost per sample make it ideal for confirming a single nucleotide variant (SNV) in a patient sample.

Small targeted panels: When analyzing fewer than 10–20 amplicons, Sanger sequencing is simpler and faster than NGS. For example, sequencing the entire coding region of a single gene (e.g., BRCA1, which has 22 exons) can be accomplished with ~30 Sanger reactions.

Clonal sequencing: Sequencing individual plasmids, bacterial clones, or phage clones requires single-read resolution. Sanger sequencing provides the full insert sequence in one reaction.

Short tandem repeat (STR) analysis: Forensic and parentage testing rely on fragment analysis, which is a variant of Sanger sequencing that measures fragment length rather than sequence.

Microbial identification: Sequencing the 16S rRNA gene (~1,500 bp) or the internal transcribed spacer (ITS) region for fungal identification is well suited to Sanger sequencing, as the full-length gene can be covered with two reactions.

When NGS is Preferred

NGS is the method of choice for applications requiring breadth or depth:

Whole-genome sequencing (WGS): Sequencing an entire human genome (~3.2 Gb) requires ~30× coverage, which is impractical with Sanger sequencing. NGS platforms generate this data in a single run.

Whole-exome sequencing (WES): Capturing and sequencing all protein-coding exons (~30 Mb) enables identification of coding variants at a fraction of WGS cost.

Targeted resequencing: Large panels (e.g., 100–500 cancer-related genes) are efficiently sequenced using NGS with hybrid capture or amplicon-based enrichment.

RNA sequencing (RNA-seq): Quantifying transcript abundance and identifying splice variants requires millions of reads, which only NGS can provide.

Metagenomics: Characterizing microbial communities requires sequencing millions of fragments from mixed populations.

Epigenetic applications: Methods such as __MASK_5 for methylation analysis and MASK_6__ for chromatin accessibility require genome-wide coverage.

Low-frequency variant detection: NGS can detect variants present at 1–5% allele frequency with sufficient coverage (500–1,000×), which is essential for somatic mutation analysis in cancer.

Hybrid Approaches

A common strategy is to use NGS for discovery and Sanger for validation. For example, a clinical diagnostic laboratory may use a targeted NGS panel to screen for mutations in 50 cancer genes, then confirm each identified variant by Sanger sequencing before reporting the result. This hybrid approach leverages the throughput of NGS and the accuracy of Sanger.

Another hybrid approach uses Sanger sequencing to fill gaps in NGS data. Regions with low coverage, high GC content, or complex repeats may be poorly sequenced by NGS; targeted Sanger sequencing can close these gaps.

Common Pitfalls and Practical Considerations

Misinterpreting Coverage and Depth

A frequent error is confusing the number of reads with coverage depth. Coverage depth (also called read depth) is the average number of times each base is sequenced. For example, 10 million reads of 150 bp from a 3 Mb targeted panel yields 500× average coverage (10,000,000 × 150 / 3,000,000 = 500). However, coverage is not uniform—GC-rich regions and repetitive elements are often under-covered. A mean coverage of 100× may still leave 5–10% of bases with <20× coverage, which is insufficient for confident variant calling.

When interpreting NGS data, always check the coverage distribution, not just the mean. The __MASK_7__ guide provides practical thresholds: 30× for germline SNV calling, 50–100× for clinical diagnostics, and 500–1,000× for low-frequency variant detection.

Ignoring Quality Scores

Both Sanger and NGS data include quality scores that indicate the probability of a base call being incorrect. A common mistake is to ignore these scores and treat all bases equally. In Sanger data, the first 20–30 bases are often low quality due to primer peaks and dye blobs; the last 100–200 bases degrade due to signal decay. In NGS data, quality scores decrease toward the 3′ end of reads.

Best practice is to:

Trim low-quality bases (e.g., Phred < Q20) before analysis
Filter reads with low mean quality
Use variant callers that incorporate quality scores (e.g., GATK HaplotypeCaller, which uses a Bayesian model that weighs quality scores)

Overlooking Cost per Sample vs per Base

The cost comparison between Sanger and NGS is often misstated. While NGS has a dramatically lower cost per base, the per-sample cost can be higher for small numbers of samples due to library preparation and the fixed cost of a sequencing run. For example, sequencing 5 amplicons from 10 samples (50 reactions total) costs approximately $250–$500 with Sanger sequencing. The same analysis by NGS would require library preparation ($30–$50 per sample = $300–$500) plus a MiSeq run ($1,000–$1,500), totaling $1,300–$2,000—even if only a fraction of the flow cell is used.

Conversely, for 1,000 samples, NGS is far more cost-effective. Always calculate the total cost for your specific sample number, including labor and analysis time, not just the per-base cost.

Other Practical Pitfalls

Sanger template quality: Contaminating RNA, salts, or residual primers in the template reduce sequencing quality. Always purify PCR products before sequencing.
Primer design: Primers should have a Tm of 55–65°C, a GC content of 40–60%, and no self-complementarity or hairpin structures. Poor primer design is the most common cause of Sanger sequencing failure.
NGS index hopping: On patterned flow cells, index sequences can be misassigned between samples. Use unique dual indexes (UDIs) to mitigate this.
PCR duplicates: Over-amplification during library preparation creates duplicate reads that inflate coverage estimates and bias variant calling. Use molecular barcodes (unique molecular identifiers, UMIs) to identify and remove duplicates.
GC bias: High GC content (>70%) causes polymerase stalling and reduced coverage. Consider using PCR-free library preparation or enzymes optimized for GC-rich templates.

Summary and Decision-Making Framework

Quick Reference Table

Parameter	Sanger Sequencing	NGS (Illumina example)
Read length	600–1,000 bp	75–300 bp (paired-end)
Reads per run	1 (per reaction)	1–20 billion
Throughput (bases/run)	~700 bp	0.3–6,000 Gb
Accuracy (per base)	>99.9%	99–99.9% (Q20–Q30)
Dominant error type	Substitution (low rate)	Substitution (Illumina), indel (Ion Torrent)
Cost per base	~$0.01	<$0.000001
Cost per sample (1 sample)	~$5–$10	$1,000–$1,500 (run cost)
Cost per sample (96 samples)	~$5–$10	$15–$30
Turnaround time	2–4 hours	1–3 days
Sample preparation complexity	Low (PCR + purification)	High (library prep)
Multiplexing	No	Yes (96–384 samples)
Best for	Single targets, variant confirmation, small clone sequencing	Whole-genome, exome, transcriptome, large panels

Final Recommendations

The choice between Sanger sequencing and NGS depends on three primary factors: the number of targets, the required throughput, and the accuracy requirements.

Choose Sanger sequencing when:

You have fewer than 20–30 samples or targets
You need to confirm a specific variant
You are sequencing individual clones or plasmids
You require read lengths >600 bp
You need results within hours

Choose NGS when:

You need whole-genome, exome, or transcriptome coverage
You have more than 50–100 samples or targets
You need to detect low-frequency variants (<10% allele frequency)
You require quantitative information (e.g., gene expression levels)
The cost per base is the primary consideration

Consider hybrid approaches when:

You need to validate NGS findings with an orthogonal method
NGS coverage is insufficient in specific regions
You are building a clinical workflow that requires both discovery and confirmation

For long-read applications, consider comparing __MASK_8 to understand the trade-offs of third-generation platforms. For sample preparation guidance, see MASK_9__.

Frequently Asked Questions

What is the main difference between Sanger sequencing and NGS?

The fundamental difference is parallelism. Sanger sequencing processes one DNA template per reaction, producing a single read of 600–1,000 bp. NGS processes millions to billions of DNA fragments simultaneously, producing massive amounts of short-read data in a single run. This difference in throughput drives all other distinctions: cost per base, scalability, and application suitability.

Which is more accurate: Sanger or NGS?

Sanger sequencing has higher per-base accuracy (>99.9%) than a single NGS read (99–99.9%). However, NGS achieves comparable or superior consensus accuracy by sequencing each base multiple times (coverage). With 30× coverage, the consensus accuracy of NGS exceeds 99.99% for most positions. Sanger remains the gold standard for confirming individual variants, but NGS with adequate coverage is equally reliable for most applications.

Can Sanger sequencing be used for whole-genome sequencing?

Technically yes, but practically no. Sequencing a human genome (~3.2 Gb) by Sanger would require approximately 4.5 million reactions (at 700 bp per read), costing millions of dollars and taking years. The Human Genome Project used Sanger sequencing but required 13 years and $3 billion. NGS accomplishes the same task in days for under $1,000.

What are the typical read lengths for Sanger and NGS?

Sanger sequencing produces reads of 600–1,000 bp. NGS read lengths vary by platform: Illumina produces 75–300 bp (paired-end reads can be merged to ~600 bp), Ion Torrent produces 200–400 bp, Pacific Biosciences produces 10,000–25,000 bp, and Oxford Nanopore produces 10,000–100,000+ bp.

How do costs compare between Sanger and NGS?

The cost comparison depends on sample number. Sanger costs approximately $5–$10 per reaction (producing ~700 bp), regardless of sample number. NGS has a high fixed cost per run ($1,000–$1,500 for a MiSeq) plus library preparation costs ($30–$50 per sample). For 1 sample, Sanger is far cheaper. For 96 samples, NGS becomes competitive. For whole-genome or transcriptome applications, NGS is the only feasible option.

What is the role of coverage in NGS?

Coverage (read depth) is the average number of times each base is sequenced. Higher coverage increases confidence in base calls and enables detection of low-frequency variants. For germline SNV calling, 30× coverage is standard. For clinical diagnostics, 50–100× is recommended. For detecting variants at 1–5% allele frequency (e.g., somatic mutations in cancer), 500–1,000× coverage is required.

Can NGS replace Sanger sequencing entirely?

No. Sanger sequencing remains essential for several applications: confirming clinically actionable variants, sequencing individual clones, analyzing short tandem repeats, and filling gaps in NGS data. Sanger is also more cost-effective for small numbers of samples and provides longer reads than short-read NGS platforms. While NGS has replaced Sanger for most large-scale applications, Sanger remains a complementary tool in the molecular biology toolkit.

Key Takeaways

Sanger sequencing is a single-template, chain-termination method producing 600–1,000 bp reads with >99.9% accuracy; NGS is a massively parallel approach producing millions to billions of short reads per run.
The choice between methods is driven by sample number, throughput requirements, and accuracy needs—not by a universal superiority of one method over the other.
NGS achieves high consensus accuracy through coverage redundancy (30× for germline, 500–1,000× for low-frequency variants), while Sanger achieves accuracy through high per-base quality.
Cost per base is dramatically lower for NGS, but per-sample cost is lower for Sanger when sample numbers are small (<20–30).
Sanger remains the gold standard for variant confirmation, clonal sequencing, and small targeted panels; NGS is essential for whole-genome, exome, transcriptome, and metagenomic applications.
Common pitfalls include misinterpreting coverage depth, ignoring quality scores, and overlooking the fixed costs of NGS runs when calculating per-sample expenses.
Hybrid approaches—using NGS for discovery and Sanger for validation—are common in clinical and research settings and leverage the strengths of both technologies.